Partners HealthCare talking merger with insurer Harvard Pilgrim

One of Massachusetts’ largest health insurers, Harvard Pilgrim, has been discussing a merger with the state’s dominant healthcare provider, Partners HealthCare, in a move that could dramatically alter the increasingly consolidated market in and around Boston.

According to the Boston Globe, Partners and Harvard Pilgrim have been talking for several months. At the same time Partners has been quite active in gaining scale, acquiring specialty hospital Massachusetts Eye and Ear earlier this year and working through a deal to acquire Rhode Island’s Care New England Health System.

“Partners HealthCare is constantly exploring new partnerships and relationships with other providers and insurers with the goal of improving the delivery of health care to patients both locally and around the world,” Partners spokesperson Rich Copp told the Globe. “Harvard Pilgrim is certainly among those organizations.”

Partners already has an insurance arm, Neighborhood Health Plan, which had been largely to blame for the system’s $108 million operational loss in 2016. Harvard Pilgrim itself has struggled financially in recent years, posting operating losses of $91.3 million in 2016 and $28.3 million last year, though the insurer said those didn’t trigger merger talks.

Adding Harvard Pilgrim’s 1.2 million members to Partners would likely attract the same kind of scrutiny as Partners’ past expansion plans, with an added wrinkle: Harvard Pilgrim was once run by current Massachusetts Gov. Charlie Baker.

Read more at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.